RxDoctor Payments Data

Meredith Floyd, MD

Family Medicine · Moncks Corner, SCNPI 1538111760

Payments from drug & device makers

$831in general payments, 2019–2025

Across 45 payments — averaging $18.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$212
  • Amarin Pharma, Inc.$150
  • Novo Nordisk$111
  • Lilly USA, LLC$89
  • Merck$85
  • Boehringer Ingelheim$56
  • plus $129 from 7 others

What the payments were for

  • Food & beverage$831100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$831 in reported general payments places this provider in the 55th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$191,946
Medicare patients
241
Services billed
3,451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$81,970
EliquisApixaban69$45,471
MounjaroTirzepatide31$30,920
MyrbetriqMirabegron53$30,331
JardianceEmpagliflozin38$29,648
LinzessLinaclotide24$16,302
Xigduo XrDapaglifloz Propaned/Metformin23$16,249
FarxigaDapagliflozin Propanediol16$9,349
PremarinEstrogens, Conjugated18$8,615
Duloxetine Hcl125$7,912
JanuviaSitagliptin Phosphate14$7,389
JanumetSitagliptin Phos/Metformin Hcl11$5,936
Bupropion XlBupropion Hcl119$5,578
Atorvastatin Calcium272$5,389
Irbesartan135$4,593

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$111$81,97055 claims
PfizerEliquis, Premarin$25$54,08687 claims
Lilly USA, LLCMounjaro$89$30,92031 claims
Boehringer IngelheimJardiance$56$29,64838 claims
MerckJanuvia, Janumet$85$13,32625 claims
AstraZenecaFarxiga$212$9,34916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Moncks Corner

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →